121686-87-1Relevant articles and documents
KRAS G12C INHIBITORS
-
, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Chiral Pool Synthesis of trans-(2S,3S)-3-Hydroxyproline and Castanodiol from S-Pyroglutamic Acid.
Herdeis, Claus,Hubmann, Hans Peter,Lotter, Hermann
, p. 119 - 128 (2007/10/02)
The Pyroglutamic acid derivative 1 was converted through several steps into Castanodiol 9 and 2S,3S-3-Hydroxyproline 11.Key steps of the reaction sequence were the stereoselective epoxidation of 1 to 2 and the regioselective ring opening of 2 to 3.BH3*S(CH3)2 reduction of the amide group of 3 and 4 resulted in a concomitant transformation of the acetal moiety into the N-benzyl protecting group.The air sensitive 5 and 6, were transformed to the stable N-Boc prolinol derivatives 7 and 8.Deprotection of 8 provided 9, while oxidation of 8 gave the protected proline derivative 10.Deprotection of 10 furnished enantiopure 2S,3S-3-Hydroxyproline 11.
SYNTHESIS OF (2R,3S)-2-HYDROXYMETHYL-3-HYDROXYPYRROLIDINE AND THE GEISSMAN-WAISS LACTONE FROM (S)-PYROGLUTAMIC ACID
Ikota, Nobuo,Hanaki, Akira
, p. 2535 - 2538 (2007/10/02)
The synthesis of (2R,3S)- and (2R,3R)-2-hydroxymethyl-3-hydroxypyrrolidine derivatives (5 and 7) and the Geisman-Waiss lactone (12) has been achieved from (S)-pyroglutamic acid.